{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-084112","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.774942+00:00","generated_at":"2026-05-17T08:35:45.027694+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CEO Wa'el Hashad steps down; Than Powell interim CEO; Joshua Hare Executive Chairman","bullets":["Wa'el Hashad resigned as CEO and board member effective August 27, 2025 to pursue other opportunities.","Than Powell, former Chief Business Officer, appointed interim CEO effective September 4, 2025; base salary $500,000 with target bonus.","Founder and CSO Dr. Joshua Hare appointed Executive Chairman; board plans national search for permanent CEO.","Powell has 25+ years pharma/biotech leadership at GSK, Eli Lilly, Surescripts, and Epulate."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-084112","json":"https://secwatch.observer/filing/0001213900-25-084112.json","markdown":"https://secwatch.observer/filing/0001213900-25-084112.md","text":"https://secwatch.observer/filing/0001213900-25-084112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025084112/0001213900-25-084112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025084112/ea0255905-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:35:45.027694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}